Wednesday, January 17, 2018

EyewireTV -- FDA Warns Imprimis Over Claims; New ASCRS Leader

In this week’s EyewireTV, the FDA issues a warning letter to Imprimis Pharmaceuticals, claiming the maker of compounded drugs made false or misleading claims about some of its formulations on the company’s website and Twitter account; and Bausch + Lomb receives CE Mark for the Stellaris Elite Vision Enhancement System, the company’s next-generation ophthalmic surgical platform. Also, the American Society of Cataract and Refractive Surgery names veteran industry executive Stephen Speares as its executive director.

Watch Video

Wednesday, January 10, 2018

EyewireTV — Kala and Sun Provide Updates on DED Drug Candidates; Late-Stage AMD Candidate Fails

In this week’s EyewireTV, Kala Pharmaceuticals reports mixed results from two late-stage studies of its potential blockbuster dry eye disease candidate KPI-121 0.25%; and Sun Pharmaceutical submits a new drug application to the FDA for dry eye drug candidate OTX-101 (cyclosporine A, ophthalmic solution 0.09%). Also, Ohr Pharmaceutical suffers a major setback as its late-stage drug candidate for wet AMD fails to reach the primary efficacy endpoint.

Watch Video

Wednesday, January 03, 2018

EyewireTV 2017 Year in Review - Part 2

In this week's EyewireTV, we take a look back at the major industry announcements and advancements in ophthalmology from the second half of 2017. The top stories include updated dry eye recommendations, the expanded commercialization of compounded drugs, femtosecond laser and OCT enhancements, manufacturing issues and setbacks of ophthalmic drug candidates, the first total solar eclipse in the United States in 37 years, the approval of the first IOL that enables refractive correction after cataract surgery, and the first gene therapy ever approved for an inherited disease.

Watch Video

Wednesday, December 27, 2017

EyewireTV 2017 Year in Review — Part 1

We take a look back at the major industry announcements and advancements in ophthalmology in the first half of 2017. The top stories include a multi-billion-dollar acquisition of a major ophthalmic device maker, the approval of a new capsulotomy system, new indications for well-known anti-VEGF agents, the launch of an intranasal tear neurostimulator, and major advancements in IOL technology.

Watch Video

Wednesday, December 20, 2017

EyewireTV - Landmark Gene Therapy Approval; New Glaucoma Treatments Launched

In this week’s EyewireTV, Spark Therapeutics receives a landmark FDA approval as its inherited retinal disease drug Luxturna (voretigene neparvovec-rzyl) becomes the first gene therapy ever approved for a genetic disease; and Aerie Pharmaceuticals receives FDA approval of Rhopressa (netarsudil ophthalmic solution 0.02%), indicated for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Also, Bausch + Lomb begins distributing its recently approved glaucoma drug Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) to US wholesale pharmaceutical distributors.

Watch Video

Wednesday, December 06, 2017

EyewireTV - FDA Approves Light Adjustable Lens; MIPS Penalties

In this week's EyewireTV, the FDA approves RxSight's Light Adjustable Lens, the first IOL to enable refractive correction after cataract surgery; and Regeneron decides to end its clinical program of combination Eylea (aflibercept) and nesvacumab for the treatment of retinal diseases. Also, AAO warns that retina specialists and others who administer Medicare Part B drugs must act now to ensure they avoid paying penalties in 2019 due to CMS' Merit-Based Incentive Payment System (MIPS).

Watch Video
Load More